GlaxoSmithKline's cancer therapy cuts risk of disease progression or death by 38%

GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients.

from Reuters: Health News https://ift.tt/2nP9nIE
https://ift.tt/xePdMM